Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy-Reference-Cited by-同舟云学术

Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy

Published:2019-05-08 Issue:1 Volume:27 Page:117-129
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Gozzi Gustavo J.,Gonzalez Daniel,Boudesco Christophe,Dias Alexandre M. M.,Gotthard Guillaume,Uyanik Burhan,Dondaine Lucile,Marcion Guillaume,Hermetet François,Denis Camille,Hardy Laurianne,Suzanne Peggy,Douhard Romain,Jego Gaetan,Dubrez Laurence^ORCID,Demidov Oleg N.,Neiers Fabrice,Briand Loïc,Sopková-de Oliveira Santos Jana,Voisin-Chiret Anne-Sophie,Garrido Carmen

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/s41418-019-0343-4.pdf

Reference50 articles.

1. Factsheet of WHO 2012 on cancer available here: http://www.cancerresearchuk.org/sites/default/files/cs_report_world.pdf

2. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med. 2015;372:2509–20.

3. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28:3485–90.

4. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:1920–8.

5. Berthenet K, Boudesco C, Collura A, Svrcek M, Richaud S, Hammann A, et al. Extracellular HSP110 skews macrophage polarization in colorectal cancer. Oncoimmunology. 2016;5:e1170264.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension;European Journal of Medicinal Chemistry;2024-12

2. Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies;Journal of Hematology & Oncology;2024-09-04

3. First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma;Leukemia;2024-06-21

4. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma;Journal of Experimental & Clinical Cancer Research;2024-05-22

5. The Chemokine CXCL7 is Correlated with LDH-A and Predicts the Prognosis of Patients with Colorectal Cancer;Frontiers in Bioscience-Landmark;2024-04-26